VYNE Therapeutics Inc. Overview
Pro stress-test →VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug. The company has undergone significant portfolio challenges in 2025 and initiated a strategic review.
Strategic Profile
Pro stress-test →VYNE also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. However, the company faces significant headwinds: repibresib missed primary endpoints in Phase 2b vitiligo trials, and VYN202 faced FDA clinical holds related to toxicology concerns. VYNE entered a definitive all-stock merger with Yarrow Bioscience, with the combined company expected to operate as Yarrow Bioscience and trade on Nasdaq as YARW, with RTW Investments committing approximately $200 million in pre-closing financing.
Competitive Landscape
Pro stress-test →VYNE competes in the topical and oral inflammatory disease treatment space. Direct competitors include companies like Repare Therapeutics, Century Therapeutics, PMV Pharmaceuticals, Neuphoria Therapeutics, and other clinical-stage immunology-focused biotechs. VYNE's BET inhibitor approach represents a differentiated mechanism, though recent clinical failures have significantly weakened its competitive position.
Industry Context
VYNE Therapeutics Inc. operates in Biopharmaceuticals - Immunology & Inflammation / Dermatology.
Key facts
Founded: 2003 · Headquarters: Bridgewater, New Jersey · Revenue: $501K (2024)